Steinwender Clemens, Blessberger Hermann, Kiblböck Daniel, Saleh Karim, Kammler Jürgen
Klinik für Kardiologie und Internistische Intensivmedizin, Kepler Universitätsklinikum Linz, Medizinische Fakultät, Johannes Kepler Universität Linz, Altenberger Straße 69, 4040, Linz, Österreich.
Herzschrittmacherther Elektrophysiol. 2018 Dec;29(4):334-339. doi: 10.1007/s00399-018-0592-9. Epub 2018 Nov 19.
Leadless pacemakers have the potential to fundamentally change the field of device therapy. As leads and generator pockets are no longer needed with this technology, many potentially dangerous complications of conventional pacemaker systems like lead fractures, lead endocarditis or pocket infections can be effectively avoided. At present, Micra™ (Medtronic Inc., Minneapolis, MN, USA) is the only commercially available leadless pacemaker. Since its first-in-human implantation in 2013, thousands of these devices have been implanted worldwide. This article presents an overview of the present clinical evidence and future perspectives of this promising new technology.
无导线起搏器有潜力从根本上改变器械治疗领域。由于这项技术不再需要导线和发生器囊袋,传统起搏器系统的许多潜在危险并发症,如导线断裂、导线心内膜炎或囊袋感染,都可以有效避免。目前,Micra™(美敦力公司,美国明尼苏达州明尼阿波利斯)是唯一可商购的无导线起搏器。自2013年首次植入人体以来,全球已植入了数千台此类设备。本文概述了这项有前景的新技术目前的临床证据和未来前景。